Skip to main content Skip to footer
American Family Children's Hospital
SHARE TEXT
 

29 protocols found



Protocol No. Title Status
UW13056 Women's Integrative Sexual Health (WISH) Program Research Database Open
NHLBI-MDS The National Myelodysplatic Syndromes (MDS) Study Open
NCI9706 Randomized phase II study to assess the role of Nivolumab as single agent to eliminate minimal residual disease and maintain remission in acute myelogenous leukemia (AML) patients after chemotherapy Open
UW16004 Phase Ib Trial of Pembrolizumab in Combination with Dinaciclib in Subject with hematologic Malignancies Open
UW16059 Patient-related Barriers to Pain Management: Revisiting the Pain Barriers Questionnaire Open
APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors Not Open
APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations Open
APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MapK Pathway Mutations Open
APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations Open
APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. Open
APEC1621B NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations Open
EAY131 Molecular Analysis for Therapy Choice (MATCH) Open
UW14108 Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy (CCTL019A2205B) Open
UW17096 Improving Survivorship Care Planning for Bone Marrow Transplant Survivors: A Sociotechnical Systems Approach Open
UW15106 Genomic analysis of long-term survivors with metastatic cancer Open
EAI141 Early Assessment of Treatment Response in AML using FLT PET/CT Imaging Open
AALL08B1 Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Open
UW16144 An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies Open
UW17120 An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA) Open
UW14113 A pilot study to assess engraftment using CliniMACS TCR-alpha/beta and CD19 depleted stem cell grafts from haploidentical donors for hematopoietic progenitor cell transplantation in patients with relapsed lymphoma Open
BMTCTN1301 A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease Open
S1612 A Randomized Phase II/III Trial of "Novel Therapeutics: Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older Open (affiliates only)
UW16057 A Pilot Randomized Control Trial of a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplant Open
AAML1331 A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid Open
E1910 A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL Negative B Lineage Acute Lymphoblastic Leukemia in Adults Open
UW17102 A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia Open
NCI9782 A Phase 1 Study of Talazoparib (BMN 673) in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors Open
UW18001 A Multicenter, Open Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated with Cancer Open
BMTCTN1506 A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy following Allogeneic Transplant for Patients with FLT3/ITD AML Open